Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (12404)	12/7/1999 9:00:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

"XOMA is making the HE method available for licensing to companies who may find it a preferable alternative to other methods. XOMA is also using the HE method as part of the technology involved in XOMA?s Genimune? targeted immunofusion molecule (TIF) program, and for the ING-1 antibody, both available for licensing." Wonder if XOMA will license either of these in my lifetime. If they do it might result in other companies having more interest in their humanization technology.